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Heart failure as a subject
for palliative care
Abstract
Heart failure (HF) is a common end stage in any structural or functional cardiac disease advanced enough to
impair the filling of the ventricles or blood ejection. If the degree of impairment makes the heart unable to
cope with the actual demands of pumping blood, the diagnosis of heart failure is justified. The heart first
disables the circulation during exercise and finally, in end-stage HF, even at rest. HF is a progressive process,
usually only slowed by the treatment currently available. Thus from diagnosis, the disease will accompany
patients for the rest of their lives, sometimes becoming the cause of death. A patient reaching end-stage
heart failure should be considered for one of four treatment options: mechanical circulatory support; con-
tinuous intravenous positive inotropic therapy; a referral for cardiac transplantation; or hospice care. Before
the patient is considered to have end-stage HF, all curable factors potentially causing a deterioration in
cardiac function have to be actively explored and corrected. This paper focuses on patients for whom
methods to improve prognosis and heart function have been exhausted. The number of such patients is
increasing continuously. This is caused by the growing incidence of heart failure, improvement in the medical
care prolonging survival, and progress in decreasing the number of sudden cardiac deaths in the early stages
of the disease.
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Introduction
The prevalence of heart failure in the European
Union is estimated at 2–3% of the general popula-
tion [1]. In Poland 700,000–750,000 people are
affected by heart failure (HF) [2, 3]. In a recent
Polish study, the average age of patients admitted
to hospital due to HF decompensation was about
70. Heart failure mostly affects elderly people: the
mean age of HF patients in developed countries is
about 75 years old. This explains the important
influence of concomitant diseases on the quality
of life, possible drug interactions and finally the
cause of death. Ischaemic aetiology is mentioned
in over 60% of patients, often with hypertension
as a concomitant disease [2]. The overall prognosis
in HF, although improving, still remains very
gloomy. About 50% of patients die within 4 years
of diagnosis [1] and the average time elapsing be-
tween diagnosis and death is very short (1.7 years
for men and 3.2 years for women) [4]. Statistical
data clearly indicate that HF is associated with a
bad prognosis and a decidedly lowered life expect-
ancy but awareness in the clinical praxis is still not
satisfactory. Modern clinical decision-making has
to be supported by clinical trial results, whereas
the primary end-point in those trials has been a
reduction of cardiovascular mortality or all-cause
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mortality. Unfortunately, quality of life or a life span
with satisfactory quality was almost never investi-
gated.  Current guidelines pay increasing attention
to the need for supportive care in end-stage HF
patients [5].
The natural history of heart failure
The current ACC/AHA classification of HF focu-
ses on a stepwise progression from the presence of
HF risk factors (Stage A), through structural heart
abnormalities (Stage B) to heart failure (Stage C),
and its end-stage phase (Stage D). The last two
stages (C and D) are the subject of functional NYHA
classification (I to IV). The development of structur-
al cardiac abnormalities can have one of three out-
comes: 1. the patient dies before developing any
symptoms; 2. the patient develops HF symptoms
which respond to treatment; and 3. the patient dies
from progressive HF. Sudden death can interrupt
this course at any time [1]. During the initial presen-
tation, many patients experience symptoms corre-
sponding to NYHA class III. After appropriate treat-
ment is instituted, some of the patients improve,
some stabilize at their current condition, and some
deteriorate despite optimal therapy. Of the patients
admitted to hospital for HF decompensation, 40%
will die or be readmitted within one year [1].
Despite unchallenged progress in treatment, the
prognosis for HF patients remains poor, often even
worse than for many cancer patients. However, pa-
tients can potentially benefit from heart transplan-
tation (there were only 325 transplantations in Po-
land during the years 2003–2007) or mechanical
circulatory support but most patients with advanced
heart failure enter the terminal phase and die [3].
The main mechanism of death in NYHA class IV is
the progressive failure of the heart as a pump.
There are several potentially reversible causes of
HF that should be ruled out prior to acknowledging
HF as being end stage and irreversible. The develop-
ment of specialized outpatient clinics would allow
competent discrimination between potentially cur-
able and true end-stage forms of HF. The interdisci-
plinary teams would ensure optimal tailoring of ther-
apy and support for patients and their families. This
means not only prompt use of reasonable modali-
ties and devices but also abandonment of redun-
dant procedures (e.g. implantation of ICD for peo-
ple with a short life expectancy). A life expectancy
shorter than one year due to HF, the patient's gen-
eral condition or concomitant diseases (often seen
in elderly people), should dictate the avoidance of
invasive procedures (e.g. ICD, CRT or cardiovascular
surgery). Refusal to use such interventions can be
seen as a way of keeping quality of life at the best
possible level.
Heart failure as a terminal disease
There are a few conditions which have to be
fulfilled for treating patients with end-stage HF prop-
erly with regard to the advancement of the disease.
First of all is the awareness of medical caregivers of
the bad prognosis. The statistical facts are usually
well known but remain without influence on clinical
praxis. HF is still treated as a relatively benign dis-
ease causing breathlessness and oedema. Conse-
quently, communication with patients and their fam-
ilies is often far from ideal. However, the tools for
predicting the outcome and the time taken for the
course of the disease, even if very sophisticated, are
imperfect [6, 7]. In a recent study it was shown that
nurses' observations anticipated, with the highest
accuracy, the probability of death within 6 months
[8]. The prognostication about life span in HF is
more difficult than for other chronic diseases. The
stable, stepwise deterioration trajectory of chronic
HF is sometimes broken abruptly by an unpredicted
worsening [9]. This worsening can be of only tem-
porary exacerbation but it can also be the last epi-
sode, finishing life [1]. Studies investigating the qual-
ity of life of patients with HF have shown that they
suffer, to at least a comparable degree, as much as
patients dying from cancer, but for many months
longer before death. Approximately 40% of patients
are unable to get out of bed or a chair for the 12
months prior to death [10], which is why the time
for scheduling palliative care should be determined
by the symptoms or degree of disability, not the
predicted live span. If a patient suffers from marked
symptoms despite optimal medical therapy, the
symptomatic approach should outweigh the caus-
ative [5]. The goals and steps in the palliative ap-
proach to HF have been given in current guidelines
for the diagnosis and treatment of acute and chronic
heart failure by the European Society of Cardiology
(Table 1) [1].
Elements of a palliative approach
to a patient with heart failure
Education
The patient and family should be informed about
the prognosis, treatment options, possible function-
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al deterioration and life expectancy [5]. An early
start to this process is preferable in order to prepare
the patient and family for settling important end-
of-life questions. It is easier to accept the need for
asking questions about treatment strategies or the
abandonment of resuscitation in case of cardiac ar-
rest when the patient is in a stable condition than
in more urgent circumstances. Even if patients
change their mind, it seems more comfortable for
them to return to a discussion that has already been
started. A lower-than-expected percentage of pa-
tients admitted for HF decompensation declare the
wish not to be resuscitated in the event of cardiac
arrest (23%). This number decreases by 40% after
discharge [11], which probably reflects the hope
that the next exacerbation of symptoms will only
be a similarly temporary event and, after treatment,
it will be possible to return to the condition preced-
ing decompensation.
Modification of current medication
Basic HF medication improves not only progno-
sis and disease progression, but also helps to con-
trol the signs and symptoms of cardiac insufficien-
cy. Thus the basic treatment should also be contin-
ued in end-stage HF. The discontinuation of treat-
ment can provoke symptom exacerbation. Lower-
ing the dose of ACEI, seldom discontinuation, in
cases of hypotension is justified only if it is symp-
tomatic. The main reason warranting the abrupt
discontinuation of ACEI is angioneurotic oedema.
Abrupt withdrawal of treatment with an ACEI can
lead to a deterioration of the patient's state and
should be avoided if possible. Beta-blockers, used
as standard treatment, should preferably not be
stopped, even in the case of HF exacerbation. In-
stead, decreasing the dose temporarily is suggest-
ed [5]. However, drugs prescribed for improving
the long-term prognosis can be revised (e.g. lipid-
lowering agents). Some controversy has arisen over
the potential harm of aspirin in advanced HF. A few
of the older studies have suggested that aspirin can
enhance the risk of rehospitalization due to the
worsening of heart failure [12]. As such, perhaps,
long after myocardial infarction in patients without
coronary stents, the discontinuation of acethylsali-
cylic acid would be reasonable if they are prone to
hypervolaemia.
The introduction of symptomatic medication
The general rules of symptomatic treatment, until
eventual studies addressing HF patients indicate
otherwise, are similar to end-of-life treatment used
in palliative care. However, it has to be remembered
that those treatment strategies have been estab-
lished for patients dying from cancer. Neuroleptics,
anxiolitycs, non-opioid analgesics and opioids, co-
analgesics and oxygen are usually prescribed for
symptom relief. In addition, the armamentarium for
the treatment of HF patients embraces drugs which
influence the cardiovascular system: positive ino-
tropic drugs and intravenous diuretics [5]. It is im-
portant in the context of palliative care to underline
the reason that the administration of drugs is for
Table 1. Goals and steps in the process of providing palliative care in patients with heart failure (HF) [1]
Patient features 1 episode of decompensation/6 months despite optimal tolerated therapy
Need for frequent or continual IV support
Chronic poor quality of life with NYHA IV symptoms
Signs of cardiac cachexia
Clinically judges to be close to the end of life
Confirm diagnosis Essential to ensure optimal treatment
Patient education Principles of self-care maintenance and management of HF
Establish an advanced Designed with the patient and family member. Reviewed regularly and
care plan includes the patient's preferences for future treatment options
Service should be The patients' care within the multidisciplinary team, to ensure optimal pharmacological
organized treatment, self-care management and to facilitate access to supportive services
Symptom management Requires frequent assessment of patients' physical, psychological, social and spiritual needs.
Patients frequently have multiple co-morbidities that need to be identified
Identifying end-stage HF Confirmation of end-stage HF is advisable to ensure that all appropriate treatment options
have been explored a plan for terminal stage of illness should be agreed upon
Breaking bad news to Explaining disease progression and a change in treatment emphasis is a sensitive issue and
the patient and family must be approached with care
Establishing new goals End-of-life care should include avoidance of circumstances which may detract from a
of care peaceful death. All current pharmacological treatment and device programmes should be
considered. Resuscitation orders should be clear
NYHA — New York Heart Associations
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symptomatic reasons and the improvement of the
quality of life, not the prolongation of life. Even if
inotropes are accused of having a negative influ-
ence on survival, they are acceptable in end-of-life
treatment when decreasing suffering becomes the
priority.
The restriction of device therapy
Implantable cardiovertor-defibrillators (ICD), with
or without cardiac resynchronization therapy (CRT),
are recommended for patients in a stable condition
with NYHA class II or III, with at least 3-6 months of
optimal therapy and a life expectancy with a good
functional status of longer than one year. Pacemak-
ers with atrial or ventricular pacing (without CRT or
ICD) may be observed in patients who have evolved
further in living with heart failure after a device has
been implanted. When the patient enters the end-
stage phase of heart failure and death is approach-
ing, it is reasonable to consider deactivating the
device or some of its functions. The main issue is
the deactivation of defibrillating capacity [5]. The
decision concerning the lack of ICD intervention in
cases of ventricular fibrillation is consistent with a
non-resuscitation decision. If death seems to be
imminent, as a consequence of advanced and pro-
gressive disease leading to irreversible damage of
the organ or system function, there is no indication
to resuscitate. Automatic interventions by the im-
planted device, attempting to interrupt the process
of dying, are useless in these circumstances and can
potentially even worsen suffering. The decision
about ICD deactivation should be discussed much
earlier with the patient, his or her family and GP.
Pacing capacity can usually be kept unchanged be-
cause this does not cause suffering and, in addi-
tion, can prevent symptoms triggered by arrhyth-
mia (e.g. syncope). However, people sometimes have
concerns about the potential possibility of pace-
makers prolonging agony. This issue is in fact more
complex and controversial than ICD deactivation.
Conclusions
The development of a palliative approach to pa-
tients with HF is an important area of treatment
which breaks down the barriers between special-
ties. The person who is suffering becomes the sub-
ject of holistic medicine. People who care about
others complying for symptoms caused by different
diseases try to solve their problems, to allow them
to spend left life time in best accesible quality, in
comfort and in quiet surroundings. To achieve this
ideal picture, a great deal has to be done. One of
the most important issues is the question of who
should be the carer: the cardiologist, palliative med-
icine specialist or a GP supported by other practitio-
ners. It seems reasonable that patients should re-
main under the supervision of the doctor who has
accompanied them during their illness. Such a solu-
tion, however difficult to organize, would give the
dying person continuity of care between the inpa-
tient and outpatient settings.
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